Schedule 13G ownership disclosure

KALARIS THERAPEUTICS INC

Common Stock, $0.0001 per value · CUSIP: 482929106

Event date: 2025-03-18

Filing-level shares
723,273
Percent of class
3.9%
  • GILEAD SCIENCES, INC.

    Shares: 723,273 · Class: 3.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001123292-25-000148
Form type
SCHEDULE 13G/A
Filer
GILEAD SCIENCES, INC.
CIK
CIK 882095
Filed
Mar 20, 2025
Reporting period
Mar 18, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub